Hironic Co. Ltd - Asset Resilience Ratio

Latest as of December 2024: 17.42%

Hironic Co. Ltd (149980) has an Asset Resilience Ratio of 17.42% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩13.94 Billion
≈ $9.45 Million USD Cash + Short-term Investments

Total Assets

₩80.01 Billion
≈ $54.22 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Hironic Co. Ltd's Asset Resilience Ratio has changed over time. Check Hironic Co. Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Hironic Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hironic Co. Ltd (149980) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩13.94 Billion 17.42%
Total Liquid Assets ₩13.94 Billion 17.42%

Asset Resilience Insights

  • Good Liquidity Position: Hironic Co. Ltd maintains a healthy 17.42% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Hironic Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Hironic Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medtronic PLC
XETRA:2M6
Medical Devices 7.91%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Anteris Technologies Global Corp
AU:AVR
Medical Devices 33.27%
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
Medical Devices 19.31%
Aroa Biosurgery Ltd
AU:ARX
Medical Devices 12.13%
EBR Systems Inc
AU:EBR
Medical Devices 54.70%
MICROPORT CARDIO.MEDTECH.
F:72X
Medical Devices 37.03%
Shinhung
KO:004080
Medical Devices 4.17%

Annual Asset Resilience Ratio for Hironic Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Hironic Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 17.42% ₩13.94 Billion
≈ $9.45 Million
₩80.01 Billion
≈ $54.22 Million
-1.27pp
2023-12-31 18.69% ₩14.78 Billion
≈ $10.02 Million
₩79.10 Billion
≈ $53.60 Million
-17.47pp
2022-12-31 36.16% ₩24.41 Billion
≈ $16.54 Million
₩67.51 Billion
≈ $45.75 Million
+3.61pp
2021-12-31 32.54% ₩20.72 Billion
≈ $14.04 Million
₩63.67 Billion
≈ $43.15 Million
-8.39pp
2020-12-31 40.93% ₩18.32 Billion
≈ $12.42 Million
₩44.76 Billion
≈ $30.33 Million
+6.53pp
2019-12-31 34.41% ₩16.12 Billion
≈ $10.93 Million
₩46.87 Billion
≈ $31.76 Million
+10.80pp
2018-12-31 23.61% ₩10.15 Billion
≈ $6.88 Million
₩43.01 Billion
≈ $29.15 Million
-18.72pp
2017-12-31 42.32% ₩21.17 Billion
≈ $14.35 Million
₩50.03 Billion
≈ $33.91 Million
-7.34pp
2016-12-31 49.67% ₩22.21 Billion
≈ $15.05 Million
₩44.72 Billion
≈ $30.31 Million
-1.80pp
2015-12-31 51.46% ₩23.60 Billion
≈ $15.99 Million
₩45.86 Billion
≈ $31.08 Million
-16.80pp
2014-12-31 68.26% ₩36.45 Billion
≈ $24.70 Million
₩53.40 Billion
≈ $36.19 Million
--
pp = percentage points

About Hironic Co. Ltd

KQ:149980 Korea Medical Devices
Market Cap
$44.36 Million
₩65.46 Billion KRW
Market Cap Rank
#22346 Global
#1380 in Korea
Share Price
₩4280.00
Change (1 day)
-4.89%
52-Week Range
₩4280.00 - ₩4775.00
All Time High
₩11460.22
About

Hironic Co., Ltd. engages in the manufacture and sale of medical and surgical equipment, and other orthopedic appliances in South Korea and internationally. It offers its products for the MFU and RF, laser, plasma, and cryotherapy. The company was founded in 2007 and is headquartered in Yongin-Si, South Korea.